Empagliflozin, Dapagliflozin And Canagliflozin Market Expansion Outlook: $10.82 Billion by 2029 Forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Empagliflozin, Dapagliflozin And Canagliflozin Market From 2025 To 2034?

The market for empagliflozin, dapagliflozin, and canagliflozin has consistently expanded over the past few years. This market is projected to expand from $9.64 billion in 2024 to reach $9.84 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 2.1%. Historically, this expansion has been driven by several factors, including the rising global prevalence of type 2 diabetes, heightened understanding of the advantages offered by SGLT2 inhibitors, an expanding elderly demographic, an uptick in obesity rates, and a greater emphasis on personalized medical treatments.

The market for empagliflozin, dapagliflozin, and canagliflozin is projected to experience consistent expansion over the upcoming years, with an anticipated growth to “$10.82 billion by 2029 at a compound annual growth rate (CAGR) of 2.4%. This projected growth can be attributed to several factors such as the increasing demand for oral diabetes medications, greater investments in diabetes research and drug development, rising healthcare expenditure, enhanced awareness and diagnosis of pre-diabetes conditions, and an increasing focus on combination therapies. Throughout the forecast period, significant trends are expected to include technological advancements, the adoption of combination therapies, the expansion of telehealth services, the application of health data analytics, and a stronger emphasis on patient data security.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp

Which Drivers Are Impacting The Empagliflozin, Dapagliflozin And Canagliflozin Market?

The rising occurrence of diabetes is projected to fuel the expansion of the empagliflozin, dapagliflozin, and canagliflozin market moving ahead. Diabetes manifests as an ongoing health condition characterized by elevated blood glucose levels, resulting from insufficient insulin generation or the body’s poor response to insulin. This growing incidence of diabetes can be linked to elements like inactive lifestyles, poor eating habits, genetic factors, urban development, and older demographics, further complicated by restricted healthcare access and escalating global obesity figures. Empagliflozin, dapagliflozin, and canagliflozin are employed in managing diabetes to reduce blood sugar by blocking sodium-glucose co-transporter-2 (SGLT2) within the kidneys, thereby encouraging glucose elimination via urine. For example, data from June 2024, provided by the National Health Service (NHS), a UK government department, showed that among those under 40, the numbers increased from 173,166 in 2022 to 216,440 in 2023. This substantial rise indicates a troubling pattern within this demographic, illustrating a swift increase in diabetes prevalence among younger age groups. Consequently, the expanding occurrence of diabetes is fueling the development of the empagliflozin, dapagliflozin, and canagliflozin market.

What Are The Major Segments Identified In The Empagliflozin, Dapagliflozin And Canagliflozin Market?

The empagliflozin, dapagliflozin and canagliflozinmarket covered in this report is segmented –

1) By Type: Empagliflozin; Dapagliflozin; Canagliflozin

2) By Application: Application I; Application II; Application III; Application IV

3) By Channel: Hospital; Pharmacy

Subsegments:

1) Empagliflozin: 10 Mg; 25 Mg; 50 Mg

2) Dapagliflozin: 5 Mg; 10 Mg

3) Canagliflozin: 100 Mg; 300 Mg

Which Competitive Trends Are Defining The Empagliflozin, Dapagliflozin And Canagliflozin Market Structure?

Major companies operating in the empagliflozin, dapagliflozin, and canagliflozin markets are focusing on developing innovative products, such as pediatric type-2 diabetes treatment, to address broader patient demographics and expand their market reach in diabetes care. Pediatric Type-2 diabetes treatment involves managing blood sugar levels through lifestyle changes, medications, and sometimes insulin therapy tailored specifically for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 years and older with type 2 diabetes. This approval is based on positive results from the T2NOW Phase III clinical trial, one of the most extensive pediatric type-2 diabetes trials to date, which showed that Farxiga significantly reduced HbA1c levels compared to placebo. The safety profile of Farxiga in this patient population was consistent with that observed in adults with type-2 diabetes. This approval is an important milestone, as oral treatment options for pediatric type-2 diabetes have been limited, and it underscores AstraZeneca’s commitment to delivering innovative treatments across cardiovascular, renal, and metabolic diseases.

Which Key Players Are Driving Competition In The Empagliflozin, Dapagliflozin And Canagliflozin Market?

Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/empagliflozin-dapagliflozin-and-canagliflozin-global-market-report

How Do Regional Market Performances Compare Within The Empagliflozin, Dapagliflozin And Canagliflozin Industry?

North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Empagliflozin, Dapagliflozin And Canagliflozin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=18350&type=smp

Browse Through More Reports Similar to the Global Empagliflozin, Dapagliflozin And Canagliflozin Market 2025, By The Business Research Company

Biofuel Enzymes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biofuel-enzymes-global-market-report

Blood Brain Barrier Technologies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-brain-barrier-technologies-global-market-report

Carcinoembryonic Antigen Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/carcinoembryonic-antigen-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795